FOR IMMEDIATE RELEASE

Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

THE SAN DIEGO SUPERCOMPUTING CENTER LICENSES GENEGO'S METACORE™ PLATFORM FOR SYSTEMS BIOLOGY PPLICATIONS

New Buffalo, Michigan, (date), 2003 — GeneGo announced today that it will license its MetaCore™ platform to the San Diego Supercomputing Center (SDSC). MetaCore™ is a proprietary computational platform for Systems Biology that combines analytical tools, data content, and algorithms for understanding the complex interconnected pathways that are affected in common human diseases. Under the agreement, the SDSC will make MetaCore™ available to SDSC and the University of California San Diego (UCSD) researchers to apply to their own research programs. GeneGo will provide training and host educational seminars, symposia, and user group meetings. Additional details about the agreement were not disclosed.

"We are pleased that one of the world's most prestigious centers for computational biosciences is licensing the MetaCore™ platform," said Dr. Tatiana Nikolskaya, CEO of GeneGo. "SDSC has consistently been at the forefront of applying leading-edge information systems to biomedical research, and their decision to license MetaCore™ is an important validation of the power and utility of the Systems Biology solution we have developed."

Several SDSC faculty members already have plans to work with MetaCore™ in their research programs. One faculty member, Dr. Phil Bourne, Professor of Pharmacology, will use MetaCore™ as part of his Encyclopedia of Life project. This in silico high-throughput proteomics project is an open collaboration that aims to develop a flexible, powerful reference system to catalog, calculate three-dimensional models, and assign biological functions for the complete proteome of every living species. Another faculty member, Dr. Shankar Subramanian, Professor of Bioengineering, will use MetaCore™ as part of his efforts in the Alliance for Cellular Signaling (AfCS) collaboration. AfCS is a large-scale collaboration designed to answer global questions about cell signaling networks to facilitate quantitative modeling and eventually lead to a full understanding of how cells interpret signals in a context-dependent manner.

"The interactions between GeneGo and SDSC have been quite fruitful in the last few months," said Professor Kim Baldridge, Director of Integrative Computational Sciences at the SDSC. "We look forward to providing MetaCore™ to the research community we serve, and to building a strong, collaborative relationship with GeneGo."

About the San Diego Supercomputing Center

The San Diego Supercomputing Center (SDSC) is a national laboratory whose mission is to develop and apply high-performance information technologies for science and society. SDSC is a research unit of the University of California, San Diego, and the leading-edge site of the National Partnership for Advanced Computational Infrastructure (NPACI), a 48-institution partnership funded by the National Science Foundation (NSF) to create computational environments for tomorrow's scientific discovery. SDSC is a recognized world leader in computational biosciences, hosting the primary Protein Data Bank web and data servers, and playing the key bioinformatics and information coordination roles for the Biomedical Informatics Research Network, the Alliance for Cell Signaling, the Joint Center for Structural Genomics, the National Biomedical Computation Resource, and the Computational Center for Macromolecular Structure. Additional information is available at www.sdsc.edu.

About GeneGo

GeneGo is a privately held company that develops technology and computational platforms for the pharmaceutical and life science industries in the rapidly growing field of Systems Biology. GeneGo offers the first commercially available computational platforms that integrate information about human genes, RNA, proteins, metabolites, and biological pathways to provide a deeper understanding of the molecular mechanisms of disease, and a broader yet more efficient approach to drug target selection, prioritization, and validation, as well as biomarker identification. The company's MetaCore™ and MetaDrug™ Platforms combine proprietary and public knowledge with the customer's own data to enable the researcher to model and predict the behavior of biological systems. GeneGo was founded in 2000 and is based in New Buffalo, Michigan. Additional information about GeneGo and MetaCore™ is available at www.genego.com.